University of Massachusetts

Other

Dana-Farber-Cancer Institute Inc.

Evelyn A Kurt-Jones

Robert W Finberg

Shenghua Zhou

Keith R Solomon

Rifat Sharif

Ashok Saluja

The present invention is directed to methods, kits, and uses of inhibitors of LCMV mediated NF-&#x3ba;B activation to treat viral infections and inflammatory conditions.

Compounds for modulating TLR2

Toll-like receptor 2 (TLR2) has been found to mediate certain effects of HSV infection, particularly in neonates. Compounds that decrease TLR2 expression or activity are useful for ameliorating such deleterious effects.

Modulation of HSV infection

The present invention provides methods of identifying candidate therapeutic agents for use in the treatment of acute pancreatitis.

Pancreatitis

It has been found that Toll-like receptor 1 and Toll-like receptor 2 (TLR2) physically interact. Antibodies that specifically bind to TLR2 and selectively inhibit induction of cytokines are also described. The invention relates to specific antibodies that selectively bind to TLR2, and to methods of identifying compounds that selectively interfere with signaling through TLR1/TLR2 complexes.

Antibodies to toll-like receptor-2

Selective inhibition of toll-like receptor-2

The present invention provides for the use of G protein binding agents for prophylactic and/or therapeutic treatments of septic shock. The present invention provides methods of using agents which bind G protein to treat a subject having or susceptible to septic shock. The present invention further pertains to compositions for treating a subject for septic shock. The composition includes an effective amount of a G protein binding agent and, optionally, an antibiotic and a pharmaceutically acceptable carrier. Other aspects of the invention include packaged agents which bind G proteins for treating septic shock.

Use of agents which bind G proteins for treating septic shock

The present invention provides for the use of G protein binding agents for prophylactic and/or therapeutic treatment of septic shock. The present invention provides methods of using agents which bind G protein to treat a subject having or susceptible to septic shock. The present invention further pertains to compositions for treating a subject for septic shock. The composition includes an effective amount of a G protein binding agent such as mastoparan and, optionally, an antibiotic and a pharmaceutically acceptable carrier. Other aspects of the invention include packaged agents which bind G proteins for treating septic shock.

Growing community of inventors

Belmont, MA, United States of America

Evelyn A Kurt-Jones